SCHEMBL26088333

SCHEMBL26088333

CC(C(=O)N1CCN(c2ccc(Cl)cc2)c2ccccc21)N1CCN(C)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DRD4 P21917 1/20 0.54
▸ KMT2A Q03164 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ LMNA P02545 3/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ TSHR P16473 2/20 0.44
▸ MAPT P10636 1/20 0.44
▸ SIGMAR1 Q99720 3/20 0.43
▸ ATM Q13315 1/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ TDP1 Q9NUW8 2/20 0.41
▸ CHRM2 P08172 1/20 0.41
▸ HTR1A P08908 1/20 0.41
▸ ADRA2A P08913 1/20 0.41
▸ BCL2 P10415 1/20 0.41
▸ CHRM1 P11229 1/20 0.41
▸ DRD1 P21728 1/20 0.41
▸ TBXA2R P21731 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30378570 1.00 DRD4 (0.54) DRD4KMT2AMEN1LMNAKDM4E
SCHEMBL30910085 0.91 DRD4 (0.51) DRD4KMT2AMEN1LMNAKDM4E
SCHEMBL26092223 0.91 DRD4 (0.51) DRD4KMT2AMEN1LMNAKDM4E
SCHEMBL30379637 0.90 KMT2A (0.47) DRD4KMT2AMEN1LMNAKDM4E
SCHEMBL26089655 0.90 KMT2A (0.47) DRD4KMT2AMEN1LMNAKDM4E
SCHEMBL30379078 0.89 DRD4 (0.50) DRD4KMT2AMEN1LMNAKDM4E
SCHEMBL26092095 0.89 DRD4 (0.50) DRD4KMT2AMEN1LMNAKDM4E
SCHEMBL26088343 0.89 DRD4 (0.47) DRD4KMT2AMEN1LMNAKDM4E
SCHEMBL30378972 0.89 DRD4 (0.47) DRD4KMT2AMEN1LMNAKDM4E
SCHEMBL30910072 0.88 KMT2A (0.47) DRD4KMT2AMEN1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118119612-A Novel compounds and pharmaceutical compositions comprising the same 萨皮恩斯生物有限公司 2024-05-31 — — CN claimed
WO-2023068755-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 주식회사 사피엔스바이오 2023-04-27 — — WO claimed
US-20250002464-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME SAPIENSBIO INC. (KR) 2025-01-02 — — US disclosed
EP-4421070-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Sapiensbio Inc. (KR) 2024-08-28 — — EP disclosed
CN-118119612-A Novel compounds and pharmaceutical compositions comprising the same 萨皮恩斯生物有限公司 2024-05-31 — — CN disclosed
WO-2023068755-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 주식회사 사피엔스바이오 2023-04-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250002464-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME RHOA, ACTR2, MFAP1 DRD4 3728/4885KMT2A 3762/4885MEN1 4510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback